

# Setmelanotide for treating obesity caused by LEPR or POMC deficiency

Information for the public

Published: 6 July 2022

[www.nice.org.uk](http://www.nice.org.uk)

Setmelanotide (Imcivree) is available on the NHS as a possible treatment for obesity and controlling hunger caused by pro-opiomelanocortin (POMC) deficiency, including proprotein convertase subtilisin/kexin type 1 or leptin receptor (LEPR) deficiency in people 6 years and over.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

These organisations can give you advice and support:

- [Obesity UK, clare@obesityuk.org.uk](mailto:clare@obesityuk.org.uk)
- [All About Obesity, admin@allaboutobesity.org](mailto:admin@allaboutobesity.org)
- [The British Obesity Society, hello@thebos.org](mailto:hello@thebos.org)

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4615-0